GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma

Tumor Biology

Volumn 37, Issue 9, 2016, Pages 12571-12577

  Attallah, Abdelfattah M ^a   El Far, Mohamed ^b   Omran, Mohamed M ^c   Abdelrazek, Mohamed A ^a   Attallah, Ahmed A ^a   Saeed, Aya M ^a   Farid, Khaled ^d  

^a Biotechnology Research Center of New Damietta   (Egypt)

^b Mansoura University   (Egypt)

^c Helwan University   (Egypt)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

Biomarkers; Diagnosis; Glypican 3; Hepatocellular carcinoma; Serum; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 3; BILIRUBIN; GLYPICAN; GPC3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; TUMOR VOLUME; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ALPHA-FETOPROTEINS; BILIRUBIN; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; GLYPICANS; HUMANS; LIVER NEOPLASMS; MIDDLE AGED;

EID: 84977155285     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5127-6     Document Type: Article

References (37)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.
2. Kelley RK, Magbanua MJ, Butler TM, et al. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015;15:206.
3. El-mezayen HA, Darwish H. Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients. Tumour Biol. 2014;35:6501–9.
4. Shariff MI, Cox IJ, Gomaa AI, et al. Hepato cellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3:353–67.
5. Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer Res. 2013;33:1013–21.
6. Attallah AM, Omran MM, Attallah AA, et al. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer. 2013;109:1657–65.
7. Filmus J, Shi W, Wong ZM, Wong MJ. Identification of a new membrane-bound heparan sulphate proteoglycan. Biochem J. 1995;311:561–5.
8. Jia HL, Ye QH, Qin LX, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007;13:1133–9.
9. Kandil D, Leiman G, Allegrettaetal M. Glypican-3 immuno-cytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007;111:316–22.
10. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89–97.
11. Chen M, Li G, Yanetal J. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta. 2013;423:105–11.
12. Wang Y, Yang H, Xu H, et al. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-fetoprotein for hepatocellular carcinoma diagnosis. J Gastroenterol Hepatol. 2014;29:597–602.
13. Ozkan H, Erdal H, Kocak, et al. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal. 2011;25:350–3.
14. Jia X, Gao Y, Zhai D, et al. Assessment of the clinical utility of glypican 3 as a serum marker for the diagnosis of hepatocellular carcinoma. Technol Cancer Res Treat. 2015. doi:10.1177/1533034615605248.
15. Perkins NJ, Schisterman EF. The inconsistency of ‘optimal’ cut points obtained using two criteria based on the receiver operating characteristics curve. Am J Epidemiol. 2006;163:670–5.
16. Zakhary NI, Mohamed MS, Khorshid O, Azer RS, Zayed N. Role of glypican-3 in the early diagnosis of hepatocellular carcinoma among Egyptian patients. J Genet Eng Biotechnol. 2012;10:73–9.
17. Gomaa AI, Hendy OM, Abou Raia GY, et al. The diagnostic value of peripheral blood glypican-3 in patients with hepatocellular carcinoma. World J Med Sci. 2012;7:105–12.
18. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.
19. Gish RG. Early detection of hepatocellular carcinoma through surveillance using biomarkers. Gastroenterol Hepatol (N Y). 2014;10:121–3.
20. Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg. 2012;203:101–6.
21. Attallah AM, El-Far M, Abdel Malak CA, et al. Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma. Clin Chim Acta. 2011;412:2310–5.
22. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306:16–25.
23. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006;30:1405–11.
24. Yang SL, Fang X, Huang ZZ, et al. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature. Dis Markers. 2014;2014:127831.
25. Liu H, Li P, Zhai Y, et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol. 2010;16:4410–5.
26. Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2013;1:593–8.
27. Subramaniam S, Kelley RK, Venook AP. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013;2:33.
28. Toyoda H, Kumada T, Osaki Y, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol. 2006;4:1528–36.
29. Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54:419–25.
30. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–8.
31. Patel M, Shariff MI, Ladep NG, et al. Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract. 2012;18:335–42.
32. Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013;12:530–47.
33. Sterling RK, Jeffers L, Gordon F, et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009;7:104–13.
34. Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817–26.
35. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (Baltimore, MD). 2012;55:483–90.
36. Ge T, Shen Q, Wang N, et al. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. Med Oncol. 2015;32:59.
37. Tangkijvanich P, Chanmee T, Komtong S, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol. 2010;25:129–37.